Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression

<p>Table S2</p>

Сохранить в:

Библиографические подробности
Главный автор:	Yun-Guang Hong (14960966) (author)
Другие авторы:	Zhigang Yang (14960969) (author), Yan Chen (14960972) (author), Tian Liu (14960975) (author), Yuyuan Zheng (14960978) (author), Chun Zhou (14960981) (author), Guo-Cai Wu (14960984) (author), Yinhui Chen (14960987) (author), Juan Xia (14960990) (author), Ruiting Wen (14960993) (author), Wenxin Liu (14960996) (author), Yi Zhao (14960999) (author), Jin Chen (14961002) (author), Xiangwei Gao (14961005) (author), Zhanghui Chen (14961008) (author)
Опубликовано:	2025
Предметы:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Drug Targets Oncoprotein & tumor suppressor drug targets Gene Regulation Posttranscriptional and translational control Hematological Cancers Leukemias Oncogenes & Tumor Suppressors
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
по: Yun-Guang Hong (14960966)
Опубликовано: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
по: Yun-Guang Hong (14960966)
Опубликовано: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
по: Yun-Guang Hong (14960966)
Опубликовано: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
по: Yun-Guang Hong (14960966)
Опубликовано: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
по: Yun-Guang Hong (14960966)
Опубликовано: (2025)

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
по: Amir T. Fathi (15313195)
Опубликовано: (2025)

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
по: Amir T. Fathi (15313195)
Опубликовано: (2025)

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
по: Ana Vujovic (15207479)
Опубликовано: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
по: Ana Vujovic (15207479)
Опубликовано: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
по: Ana Vujovic (15207479)
Опубликовано: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
по: Ana Vujovic (15207479)
Опубликовано: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
по: Ana Vujovic (15207479)
Опубликовано: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
по: Ana Vujovic (15207479)
Опубликовано: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
по: Ana Vujovic (15207479)
Опубликовано: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
по: Ana Vujovic (15207479)
Опубликовано: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
по: Ana Vujovic (15207479)
Опубликовано: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
по: Long Jiang (14956159)
Опубликовано: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
по: Long Jiang (14956159)
Опубликовано: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
по: Long Jiang (14956159)
Опубликовано: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
по: Yuanqing Ma (15052437)
Опубликовано: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
по: Yuanqing Ma (15052437)
Опубликовано: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
по: Yuanqing Ma (15052437)
Опубликовано: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
по: Yuanqing Ma (15052437)
Опубликовано: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
по: Yuanqing Ma (15052437)
Опубликовано: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
по: Yuanqing Ma (15052437)
Опубликовано: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
по: Yuanqing Ma (15052437)
Опубликовано: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
по: Yuanqing Ma (15052437)
Опубликовано: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
по: Smruthy Sivakumar (15053536)
Опубликовано: (2025)

Supplementary Tables from Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib
по: Xiangyu Zeng (17314920)
Опубликовано: (2025)

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
по: Zev A. Wainberg (15047031)
Опубликовано: (2025)

Figure S1 from Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR
по: Jeffrey D. Mandell (14963909)
Опубликовано: (2025)

Figure S1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
по: Nicolas A. Giraldo (15050937)
Опубликовано: (2025)

Figure s2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
по: Nicolas A. Giraldo (15050937)
Опубликовано: (2025)

Supplementary Data 1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
по: Nicolas A. Giraldo (15050937)
Опубликовано: (2025)

Supplementary Data 2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
по: Nicolas A. Giraldo (15050937)
Опубликовано: (2025)

Supplementary Data 3 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
по: Nicolas A. Giraldo (15050937)
Опубликовано: (2025)

Supplementary Data1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
по: Nicolas A. Giraldo (15050937)
Опубликовано: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
по: Yufang Bao (15386826)
Опубликовано: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
по: Yufang Bao (15386826)
Опубликовано: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
по: Yufang Bao (15386826)
Опубликовано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_i40rljcn6ptia1f17jl7v8ita4